Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$144 Million

DermTech

Follow-on Offering

Lead Left Bookrunner, January 2021

DermTech, Inc. is a leading genomics company developing and marketing non-invasive genomics tests that seek to transform the practice of dermatology and related fields.  DermTech’s mission is to transform dermatology with its non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.

More Like This

Jan 2021
$225 Million

Follow-on Offering

Bookrunner

View Details
Jan 2021
$144 Million

Follow-on Offering

Bookrunner

View Details
Dec 2020
$145 Million

Follow-on Offering

Lead Left Bookrunner

View Details